查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591947

高胆固醇症治疗药物市场：按作用机制、疾病类型和药物类别 - 全球预测 2025-2030

Hypercholesterolemia Drug Market by Mechanism of Action, Type of Disease (Familial hypercholesterolemia, Non-Familial hypercholesterolemia ), Drug Class - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

高胆固醇症治疗市场2023年估值为202.5亿美元，预计到2024年将达214.3亿美元，复合年增长率为6.32%，预计到2030年将达到311亿美元。

高胆固醇症血症药物市场包括一系列旨在降低血液中高胆固醇水平（称为高胆固醇症）的药物治疗。高胆固醇症会增加心血管疾病的风险，并且通常受到生活方式和遗传因素的影响。这些药物的需求是由于不健康的饮食、久坐的生活方式和人口老化等因素导致高胆固醇症在全球流行。这些药物（如他汀类药物、PCSK9 抑制剂、胆固醇吸收抑制剂和 bempedoic 酸）的应用范围和最终用途正在扩大，因为医疗保健提供者透过各种製剂直接向患者给药。市场开拓洞察表明，关键的成长要素是心血管健康意识的不断提高以及研究和开发的进步，这些进步促进了疗效和安全性更高的新药的开发。此外，不断增长的医疗保健支出和旨在降低心血管疾病发病率的政府措施也推动了市场扩张。然而，药品成本上涨、严格监管和潜在副作用等挑战可能会阻碍成长。一个显着的机会在于生技药品和个人化医疗，它们有望提供具有潜在较少副作用的标靶治疗选择。公司可以透过投资创新的药物输送系统并利用人工智慧和资料分析来个人化患者照护来抓住这些机会。限制包括学名药的竞争以及需要大规模临床试验来检验新治疗方法。鑑于市场的动态特性，以技术快速进步和消费者偏好不断变化为特征，创新和研究正在推动以患者为中心的解决方案的开发，加强患者对数位健康工具的依从性，并重点应放在探索联合治疗上血脂管理。总体而言，高胆固醇症治疗市场提供了巨大的成长机会，但也存在需要策略导航和持续创新的挑战。

主要市场统计
基准年[2023] 202.5亿美元
预测年份 [2024] 214.3亿美元
预测年份 [2030] 311亿美元
复合年增长率（%） 6.32%

市场动态：揭示快速发展的高高胆固醇症治疗市场的关键市场洞察

高胆固醇症药物市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球心臟病发病率不断上升
    • 不健康饮食习惯的增加以及便利性食品和加工食品消费的增加
    • 私人和公共实体增加消费者医疗保健和基础设施支出
  • 市场限制因素
    • 市场上替代品的可用性
    • 消费者健康意识与健康饮食习惯
  • 市场机会
    • 新药引进的科技进步
    • 跨地区联合治疗的使用增加
  • 市场挑战
    • 品牌药与学名药之间的竞争

波特的五力战略工具驾驭高胆固醇症药物市场

波特的「五力」框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解高胆固醇症药物市场的外部影响

外部宏观环境因素在塑造高胆固醇症治疗药物市场的表现动态中起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解高胆固醇症治疗药物市场的竞争状况

高胆固醇症治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵高高胆固醇症市场供应商的绩效评估

FPNV 定位矩阵是评估高胆固醇症治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划高胆固醇症治疗药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对高胆固醇症治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球心臟病发生率增加
      • 不健康饮食习惯的增加以及方便食品和加工食品的消费增加
      • 私营和公共部门增加消费者医疗保健和基础设施支出
    • 抑制因素
      • 市场上替代品的可用性
      • 消费者对健康和健康饮食的认识
    • 机会
      • 新药引进的科技进步
      • 全部区域联合治疗的使用增加
    • 任务
      • 品牌药与学名药之间的竞争
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章高胆固醇症治疗药物市场按作用机制

  • 胆汁酸螯合剂
  • 纤维酸衍生物
  • HMG-CoA还原酶抑制剂
  • 烟碱酸

第七章依疾病类型分類的高胆固醇症治疗药物市场

  • 遗传性高胆固醇症（FH）
  • 遗传性高胆固醇症（FH）

第八章按药物类别分類的高胆固醇症治疗药物市场

  • 非他汀类药物
  • 他汀类药物

第九章北美和南美高高胆固醇症血症治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太地区高胆固醇症血症治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的高胆固醇症治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbvie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • AtheroNova Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
Product Code: MRR-43127F727989

The Hypercholesterolemia Drug Market was valued at USD 20.25 billion in 2023, expected to reach USD 21.43 billion in 2024, and is projected to grow at a CAGR of 6.32%, to USD 31.10 billion by 2030.

The hypercholesterolemia drug market encompasses a range of pharmaceutical treatments aimed at lowering high levels of cholesterol in the blood, a condition known as hypercholesterolemia. This condition increases the risk of cardiovascular diseases and is often influenced by lifestyle and genetic factors. The necessity of these drugs stems from the significant global prevalence of hypercholesterolemia, driven by factors such as unhealthy diets, sedentary lifestyles, and an aging population. The application and end-use scope of these drugs are widespread, involving direct administration to patients by healthcare providers through various formulations like statins, PCSK9 inhibitors, cholesterol absorption inhibitors, and bempedoic acid, among others. Market insights reveal that a major growth driver is the rising awareness of cardiovascular health, coupled with advances in R&D facilitating the development of novel drugs that offer improved efficacy and safety profiles. Additionally, increasing healthcare spending and government initiatives targeted at reducing cardiovascular disease incidences bolster market expansion. However, challenges such as high drug costs, stringent regulatory pathways, and potential side effects may hamper growth. A notable opportunity lies in biologics and personalized medicine, which promise targeted treatment options with potentially fewer side effects. Companies are advised to invest in innovative drug delivery systems and leverage AI and data analytics for personalized patient care to seize these opportunities. Limitations include generic competition and the necessity for large-scale clinical trials to validate new treatments. Given the dynamic nature of the market, characterized by rapid technological advancements and shifting consumer preferences, innovation and research should focus on developing patient-centric solutions, enhancing patient adherence through digital health tools, and exploring combination therapies for comprehensive lipid management. Overall, the hypercholesterolemia drug market presents significant opportunities for growth, albeit with challenges that demand strategic navigation and continuous innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 20.25 billion
Estimated Year [2024] USD 21.43 billion
Forecast Year [2030] USD 31.10 billion
CAGR (%) 6.32%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hypercholesterolemia Drug Market

The Hypercholesterolemia Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of heart disorders worldwide
    • Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
    • Increasing consumer healthcare spending and infrastructure spending by private and public organizations
  • Market Restraints
    • Availability of alternative substitutes in the market
    • Consumer awareness on healthy and fit diet
  • Market Opportunities
    • Technological advancements in introduction of novel drugs
    • Rising utilization of combination therapies across regions
  • Market Challenges
    • Competition from generic versions of branded drugs

Porter's Five Forces: A Strategic Tool for Navigating the Hypercholesterolemia Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hypercholesterolemia Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hypercholesterolemia Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hypercholesterolemia Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hypercholesterolemia Drug Market

A detailed market share analysis in the Hypercholesterolemia Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hypercholesterolemia Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hypercholesterolemia Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hypercholesterolemia Drug Market

A strategic analysis of the Hypercholesterolemia Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hypercholesterolemia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Alnylam Pharmaceuticals Inc., Amgen Inc., AstraZeneca PLC, AtheroNova Inc., Aurobindo Pharma Limited, Cipla Limited, Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, Esperion Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals Inc., Mylan N.V., Novartis AG, Pfizer Inc., and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Hypercholesterolemia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mechanism of Action, market is studied across Bile Acid Sequestrants, Fibric Acid Derivatives, HMG-CoA Reductase Inhibitors, and Nicotinic Acid.
  • Based on Type of Disease, market is studied across Familial hypercholesterolemia (FH) and Non-Familial hypercholesterolemia (FH).
  • Based on Drug Class, market is studied across Non-Statins and Statins.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of heart disorders worldwide
      • 5.1.1.2. Rising unhealthy food habits coupled with increasing consumption of convenience and processed food
      • 5.1.1.3. Increasing consumer healthcare spending and infrastructure spending by private and public organizations
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative substitutes in the market
      • 5.1.2.2. Consumer awareness on healthy and fit diet
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in introduction of novel drugs
      • 5.1.3.2. Rising utilization of combination therapies across regions
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from generic versions of branded drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hypercholesterolemia Drug Market, by Mechanism of Action

  • 6.1. Introduction
  • 6.2. Bile Acid Sequestrants
  • 6.3. Fibric Acid Derivatives
  • 6.4. HMG-CoA Reductase Inhibitors
  • 6.5. Nicotinic Acid

7. Hypercholesterolemia Drug Market, by Type of Disease

  • 7.1. Introduction
  • 7.2. Familial hypercholesterolemia (FH)
  • 7.3. Non-Familial hypercholesterolemia (FH)

8. Hypercholesterolemia Drug Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Non-Statins
  • 8.3. Statins

9. Americas Hypercholesterolemia Drug Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Hypercholesterolemia Drug Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Hypercholesterolemia Drug Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Alnylam Pharmaceuticals Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. AtheroNova Inc.
  • 6. Aurobindo Pharma Limited
  • 7. Cipla Limited
  • 8. Daiichi Sankyo Company, Limited
  • 9. Dr. Reddy's Laboratories Ltd
  • 10. Eli Lilly and Company
  • 11. Esperion Therapeutics, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Ionis Pharmaceuticals Inc.
  • 14. Mylan N.V.
  • 15. Novartis AG
  • 16. Pfizer Inc.
  • 17. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HYPERCHOLESTEROLEMIA DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYPERCHOLESTEROLEMIA DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYPERCHOLESTEROLEMIA DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FIBRIC ACID DERIVATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY HMG-COA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NICOTINIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-FAMILIAL HYPERCHOLESTEROLEMIA (FH), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY NON-STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY TYPE OF DISEASE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM HYPERCHOLESTEROLEMIA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. HYPERCHOLESTEROLEMIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. HYPERCHOLESTEROLEMIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023